osimertinib,lazertinib,amivantamab-vmjw
astrazeneca,yuhan corp,janssen,genmab
['chrysalis-2']
chrysalis-2 cohort a. common mut post osi and chemo. 2-14 lines of prior tx!. wow; orr 33%; mpfs 5.1m; mos 14.8m #asco22 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.